<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bugge C</submitter><funding>Norges Forskningsråd</funding><funding>Bristol-Myers Squibb</funding><pagination>e050564</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8477316</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(9)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>The objective of this study was to investigate the use of, and predictors for, pharmaceutical anticancer treatment (PACT) towards the end of a patient's life in a country with a public healthcare system.&lt;h4>Design&lt;/h4>Retrospective registry study.&lt;h4>Setting&lt;/h4>Secondary care in Norway.&lt;h4>Participants&lt;/h4>All Norwegian patients with cancer (International Classification of Diseases tenth revision (ICD-10) codes C00-99, D00-09, D37-48) in contact with a somatic hospital in Norway between 2009 and 2017 (N=420 655). Analyses were performed on a subsample of decedents with follow-back time of more than 1 year (2013-2017, N=52 496).&lt;h4>Interventions&lt;/h4>N/A.&lt;h4>Primary and secondary outcome measures&lt;/h4>Proportion of patients receiving PACT during the last year and month of </pubmed_abstract><journal>BMJ open</journal><pubmed_title>What are determinants of utilisation of pharmaceutical anticancer treatment during the last year of life in Norway? A retrospective registry study.</pubmed_title><pmcid>PMC8477316</pmcid><funding_grant_id>272493</funding_grant_id><pubmed_authors>Sæther EM</pubmed_authors><pubmed_authors>Kaasa S</pubmed_authors><pubmed_authors>Bugge C</pubmed_authors><pubmed_authors>Melberg HO</pubmed_authors><pubmed_authors>Sonbo Kristiansen I</pubmed_authors></additional><is_claimable>false</is_claimable><name>What are determinants of utilisation of pharmaceutical anticancer treatment during the last year of life in Norway? A retrospective registry study.</name><description>&lt;h4>Objectives&lt;/h4>The objective of this study was to investigate the use of, and predictors for, pharmaceutical anticancer treatment (PACT) towards the end of a patient's life in a country with a public healthcare system.&lt;h4>Design&lt;/h4>Retrospective registry study.&lt;h4>Setting&lt;/h4>Secondary care in Norway.&lt;h4>Participants&lt;/h4>All Norwegian patients with cancer (International Classification of Diseases tenth revision (ICD-10) codes C00-99, D00-09, D37-48) in contact with a somatic hospital in Norway between 2009 and 2017 (N=420 655). Analyses were performed on a subsample of decedents with follow-back time of more than 1 year (2013-2017, N=52 496).&lt;h4>Interventions&lt;/h4>N/A.&lt;h4>Primary and secondary outcome measures&lt;/h4>Proportion of patients receiving PACT during the last year and month of </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Sep</publication><modification>2025-04-04T20:12:24.4Z</modification><creation>2022-02-11T11:56:29.555Z</creation></dates><accession>S-EPMC8477316</accession><cross_references><pubmed>34580099</pubmed><doi>10.1136/bmjopen-2021-050564</doi></cross_references></HashMap>